Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.)

Read More  
3 min read

FiEE, Inc. Closes Its First Day of Trading on NASDAQ

Company resumed trading under its existing symbol "MINM" HONG KONG, June 2, 2025 /PRNewswire/ -- FiEE, Inc. (NASDAQ:MINM) ("FiEE, Inc." or the "Company"), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, commenced the trading of its common stock on Monday, June 2, 2025 on the Nasdaq Capital Market under the ticker symbol "MINM".

Read More  
7 min read

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”).

Read More  
4 min read

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025

Read More  
6 min read

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that the Company entered into a securities purchase agreement (“Agreement”) with investor David Lazar (“Lazar”)..

Read More  
6 min read

LQR House Inc. Announces Change of Ticker Symbol From "LQR" to "YHC" Effective December 16, 2024

MIAMI BEACH, FL / ACCESSWIRE / December 13, 2024 / LQR House Inc. (the "Company" or "LQR House") (NASDAQ:LQR), a niche e-commerce platform specializing in the spirits and beverage industry, today announced that its shares of common stock will begin trading under the new ticker symbol "YHC" on the Nasdaq Capital Market prior to the market open on December 16, 2024.

Read More  
12 min read

Activist investor David Lazar to invest $3M in LQR House

LQR House (NASDAQ:LQR) said on Wednesday that it has entered into a securities purchase agreement with activist investor David Lazar. Under the agreement, Lazar has committed to providing $3M in funding to LQR House.

Read More  
2 min read

David E. Lazar Announces Ownership Interest in Minim, Inc.

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- David E. Lazar, an experienced private investor, today filed a Schedule 13D announcing his acquisition of 2,000,000 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") of Minim, Inc. ("Minim" or the "Company"). Each share of Series A Preferred Stock is convertible into 1.4 shares of the Company's common stock ("Common Stock").

Read More  
1 min read

Titan Pharmaceuticals Shares Double on Reverse Merger Deal

Titan Pharmaceuticals shares rallied after the company entered into an agreement to combine with KE Sdn. Bhd. in a reverse merger .Shares in premarket trading on Tuesday more than doubled to $10.38.

Read More  
1 min read

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“TTNP” or the “Company”) with 9.9% of the Company’s outstanding shares, today issued the following statement:

Read More  
1 min read

OpGen Announces Acquisition of Preferred Stock by David Lazar

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million.

Read More  
3 min read

Minim Rises After Investor David Lazar Buys 2M Preferred Shares

Shares of Minim rose after investor David E. Lazar agreed to buy 2 million preferred shares of the provider of WiFi security software.

Read More  
1 min read